

# Andrew S Artz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7565804/publications.pdf>

Version: 2024-02-01

115  
papers

3,295  
citations

201674

27  
h-index

155660

55  
g-index

115  
all docs

115  
docs citations

115  
times ranked

3848  
citing authors

#	ARTICLE	IF	CITATIONS
1	Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. <i>Cancer</i> , 2022, 128, 529-535.	4.1	17
2	Unexplained anemia of aging: Etiology, health consequences, and diagnostic criteria. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 891-899.	2.6	17
3	High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	4
4	Total Marrow and Lymphoid Irradiation with Post-Transplantation Cyclophosphamide for Patients with AML in Remission. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 368.e1-368.e7.	1.2	4
5	Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, 63, 1220-1226.	1.3	2
6	Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2022, 196, .	2.5	6
7	Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL. <i>Blood Advances</i> , 2022, 6, 4936-4948.	5.2	7
8	Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 255.e1-255.e9.	1.2	6
9	Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. <i>Journal of Clinical Oncology</i> , 2021, 39, 1001-1009.	1.6	22
10	Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (<sc>HMA</sc> or liposomal daunorubicin<sc>CPX</sc>). <i>American Journal of Hematology</i> , 2021, 96, E196-E200.	4.1	10
11	The Cancer and Aging Research Group (CARG) infrastructure: The clinical implementation core. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1164-1165.	1.0	4
12	Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. <i>Journal of Geriatric Oncology</i> , 2021, 12, 585-591.	1.0	10
13	Advances in Management for Older Adults With Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2021, 39, 2102-2114.	1.6	24
14	Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2464-2470.	2.4	8
15	Characterize, Optimize, and Harmonize: Caring for Older Adults With Hematologic Malignancies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e266-e274.	3.8	3
16	Breaking the Age Barrier: Physicians' Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 617.e1-617.e7.	1.2	14
17	Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes. <i>Blood Cancer Journal</i> , 2021, 11, 125.	6.2	2
18	Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 993.e1-993.e8.	1.2	4

#	ARTICLE	IF	CITATIONS
19	Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience. <i>Blood</i> , 2021, 138, 3037-3037.	1.4	0
20	Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens. <i>Bone Marrow Transplantation</i> , 2021, , .	2.4	2
21	A Randomized Open Label Pilot Study of <i>Clostridium Butyricum</i> Miyairi 588 (CBM588) in Recipients of Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 334-334.	1.4	1
22	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Ph-like ALL. <i>Blood</i> , 2021, 138, 3955-3955.	1.4	0
23	Sarcopenia Is a Clinically Relevant and Independent Predictor of Health Outcomes after Chimeric Antigen Receptor T-Cell Therapy for Lymphoma. <i>Blood</i> , 2021, 138, 2502-2502.	1.4	6
24	The Impact of Letemovir (LTV) Prophylaxis on Early Cytomegalovirus Infection (CMVi) and Outcomes in the Adult Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients with High-Risk Donor Type. <i>Blood</i> , 2021, 138, 1776-1776.	1.4	0
25	Social Vulnerability Is a Clinically Important Predictor of Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 842-842.	1.4	1
26	Allogeneic hematopoietic cell transplantation for older patients. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 254-263.	2.5	18
27	Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 333-342.	2.0	30
28	Use of geriatric assessment in hematopoietic cell transplant. <i>Journal of Geriatric Oncology</i> , 2020, 11, 225-236.	1.0	25
29	Markers of Iron Flux during Testosterone-Mediated Erythropoiesis in Older Men with Unexplained or Iron-Deficiency Anemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3396-3403.	3.6	7
30	Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. <i>Blood Advances</i> , 2020, 4, 2810-2820.	5.2	47
31	Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2020, 55, 2204-2206.	2.4	5
32	Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1193-1199.	4.1	28
33	Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. <i>Bone Marrow Transplantation</i> , 2020, 55, 1161-1168.	2.4	11
34	Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1025-1027.	2.0	20
35	Transplant Physicians' Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) Tool. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S45-S46.	2.0	4
36	Securing the graft during pandemic: are we ready for cryopreservation for all?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e145-e146.	2.0	14

#	ARTICLE	IF	CITATIONS
37	A reduced transferrin saturation is independently associated with excess morbidity and mortality in older adults with heart failure and incident anemia. <i>International Journal of Cardiology</i> , 2020, 309, 95-99.	1.7	13
38	A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 599-606.	5.2	9
39	Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2335-2345.	2.0	28
40	Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2019, 60, 629-638.	1.3	4
41	Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. <i>Leukemia</i> , 2019, 33, 2599-2609.	7.2	76
42	Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. <i>Blood Advances</i> , 2019, 3, 1858-1867.	5.2	25
43	Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. <i>Blood Advances</i> , 2019, 3, 3488-3498.	5.2	62
44	The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases. <i>Blood</i> , 2019, 133, 754-762.	1.4	40
45	Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors. <i>Blood</i> , 2019, 134, 4176-4176.	1.4	3
46	Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A Multicenter Retrospective Study. <i>Blood</i> , 2019, 134, 4606-4606.	1.4	5
47	Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 1956-1956.	1.4	2
48	Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS. <i>Blood</i> , 2019, 134, 3324-3324.	1.4	0
49	Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 997-1004.	2.0	18
50	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
51	Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 359-365.	2.0	20
52	Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. <i>Blood Advances</i> , 2018, 2, 1198-1206.	5.2	21
53	Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2216-2223.	2.0	18
54	Another reason to encourage psychosocial risk assessment in hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1416-1417.	2.4	1

#	ARTICLE	IF	CITATIONS
55	Risk Score for the Development of Venous Occlusive Disease after Allogeneic Hematopoietic Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2072-2080.	2.0	50
56	Access and Referral Barriers to Autologous and Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Cancer: A Systematic Review with a Specific Focus on Geriatric Population. <i>Blood</i> , 2018, 132, 2245-2245.	1.4	1
57	Pembrolizumab for the Treatment of Disease Relapse Following Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 3415-3415.	1.4	11
58	Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study. <i>Blood</i> , 2018, 132, 2170-2170.	1.4	0
59	Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 4073-4073.	1.4	0
60	Association of Testosterone Levels With Anemia in Older Men. <i>JAMA Internal Medicine</i> , 2017, 177, 480.	5.1	180
61	Reprint of: Aging: Treating the Older Patient. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S10-S17.	2.0	4
62	De Novo Development of Bronchiectasis in Patients With Hematologic Malignancy. <i>Chest</i> , 2017, 152, 683-685.	0.8	12
63	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. <i>Blood</i> , 2017, 130, 1156-1164.	1.4	210
64	Aging: Treating the Older Patient. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 193-200.	2.0	23
65	Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2017, 92, 42-49.	4.1	46
66	Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-CD25 T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 4003-4011.	1.6	258
67	Renal Toxicity Associated with Salsalate in Elderly Adults with Anemia. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 898-899.	2.6	2
68	The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. <i>Haematologica</i> , 2016, 101, 1426-1433.	3.5	53
69	Biologic vs physiologic age in the transplant candidate. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 99-105.	2.5	37
70	Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1424-1430.	2.0	18
71	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1348-1356.	2.0	76
72	Survivorship care for older adults with cancer: U13 conference report. <i>Journal of Geriatric Oncology</i> , 2016, 7, 305-312.	1.0	34

#	ARTICLE	IF	CITATIONS
73	Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2100-2103.	2.0	42
74	Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. <i>Leukemia and Lymphoma</i> , 2016, 57, 1807-1813.	1.3	9
75	Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 679-679.	1.4	3
76	Evaluation of a pre-transplant serum biomarker score for allogeneic hematopoietic stem cell transplant (HCT) and association with clinical factors.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18537-e18537.	1.6	0
77	Excellent Clinical Outcome for Relapsed and Refractory Lymphoma Patients with Haplo-Cord Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 3496-3496.	1.4	0
78	The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1251-1257.	2.0	14
79	Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1830-1838.	2.0	12
80	Unexplained anaemia in the elderly is characterised by features of low grade inflammation. <i>British Journal of Haematology</i> , 2014, 167, 286-289.	2.5	23
81	Allotransplantation for Patients Age <math>\geq 40</math> Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 960-968.	2.0	37
82	Geriatric Assessment (GA) to Predict Survival in Older Allogeneic Hematopoietic Cell Transplantation (HCT) Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S39-S40.	2.0	3
83	Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. <i>Haematologica</i> , 2014, 99, 1373-1379.	3.5	213
84	Pre-transplant serum ferritin is prognostic but is it useful?. <i>Leukemia and Lymphoma</i> , 2013, 54, 1133-1134.	1.3	2
85	Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?. <i>Blood</i> , 2013, 121, 2567-2573.	1.4	120
86	High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML). <i>Leukemia and Lymphoma</i> , 2012, 53, 445-450.	1.3	20
87	Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 913-921.	2.0	40
88	From Biology to Clinical Practice: Aging and Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S40-S45.	2.0	20
89	Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. <i>Blood</i> , 2011, 118, 6438-6445.	1.4	158
90	Unexplained Anemia Predominates Despite an Intensive Evaluation in a Racially Diverse Cohort of Older Adults From a Referral Anemia Clinic. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2011, 66A, 925-932.	3.6	92



#	ARTICLE	IF	CITATIONS
91	Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401. <i>Journal of Clinical Oncology</i> , 2011, 29, 1290-1296.	1.6	318
92	A Phase II Prospective Feasibility Study of Clofarabine Cyto-reduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes. <i>Blood</i> , 2011, 118, 496-496.	1.4	0
93	Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. <i>Leukemia and Lymphoma</i> , 2010, 51, 2240-2249.	1.3	40
94	Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2010, 51, 995-1006.	1.3	16
95	Reduction of Imatinib Concentration After Gastric Bypass Surgery. <i>Blood</i> , 2010, 116, 4948-4948.	1.4	9
96	Unexplained Anemia In the Elderly (UAE) Predominates as the Major Anemia Category In Racially Diverse Cohort of Older Persons Despite An Intensive Evaluation. <i>Blood</i> , 2010, 116, 3215-3215.	1.4	1
97	Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 610-617.	2.0	58
98	Pretreatment C-Reactive Protein Is a Predictor for Outcomes after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1209-1216.	2.0	75
99	Separating correlation from prediction: C-reactive protein and infectious complications after chemotherapy for acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 381-382.	1.3	0
100	Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for Patients Lacking HLA Identical Donors. <i>Blood</i> , 2008, 112, 3015-3015.	1.4	1
101	Alemtuzumab Reduces Chronic Graft Versus Host Disease (cGVHD) and Treatment Related Mortality (TRM) after Reduced Intensity Conditioning for AML and MDS.. <i>Blood</i> , 2007, 110, 1076-1076.	1.4	2
102	Prospective Measurement of BK Virus Blood and Urine Levels, and Associations with Morbidity, in Recipients of Allogeneic Hematopoietic Stem Cell Transplants.. <i>Blood</i> , 2007, 110, 1973-1973.	1.4	0
103	Unrelated Donor (URD) Searches in African-Americans with Hematologic Malignancies: Paucity of HLA Identical Donors.. <i>Blood</i> , 2007, 110, 5064-5064.	1.4	0
104	Performance Status and Comorbidity Predict Transplant-Related Mortality After Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 954-964.	2.0	122
105	Order of patient entry influences outcome for metastatic renal cell cancer after non-myeloablative allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2006, 132, 747-754.	2.5	8
106	Phase I Study of XK469R (NSC 698215), a Quinoxaline Phenoxypropionic Acid Derivative, in Patients with Refractory Hematological Malignancies.. <i>Blood</i> , 2006, 108, 1952-1952.	1.4	0
107	New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).. <i>Blood</i> , 2006, 108, 3675-3675.	1.4	0
108	A Phase II Trial of Sequential Chemotherapy With Docetaxel and Methotrexate Followed by Gemcitabine and Cisplatin for Metastatic Urothelial Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 109-113.	1.3	7

#	ARTICLE	IF	CITATIONS
109	Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen.. Blood, 2005, 106, 2022-2022.	1.4	1
110	Alemtuzumab (Campath 1-H) Exposure Correlates with Risk of Chronic Graft vs Host Disease and CMV Viremia after Allogeneic Transplantation.. Blood, 2005, 106, 1818-1818.	1.4	0
111	Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).. Blood, 2004, 104, 1145-1145.	1.4	11
112	Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden.. Blood, 2004, 104, 2321-2321.	1.4	1
113	Conditioning with Fludarabine (Flu)-Alkylator Is More Effective Cyto-reduction Than Cyclophosphamide-Total Body Irradiation (Cy/TBI) for Refractory, Progressive Chronic Lymphatic Leukemia (CLL).. Blood, 2004, 104, 5045-5045.	1.4	0
114	Practical Implementation of Universal Hepatitis B Virus Screening for Patients With Cancer. JCO Oncology Practice, 0, , .	2.9	0
115	A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Advances, 0, , .	5.2	3